long been impossible to generate strong evidence for that contribution suggests strongly that the most efficient way to obtain such evidence will be to unmask it by removing the types of damage for which such evidence already exists: in other words, to implement SENS.
Warner also repeats a remarkable inference that has been made and refuted previously: 5 that the lack of life extension effects of any SENS strand in isolation constitutes evidence that they will also fail in combination. Since the only interventions that have to date reproducibly increased the maximum lifespan of any mammal (excluding short-lived strains) are merely elicitations of the organism's evolved response to nutrient deprivation or genetic emulations of that response, it seems quite reasonable to conclude that the time has come to explore more complex, composite interventions if we wish to postpone aging more than such elicitation can achieve.
Finally in this section, Warner highlights the overoptimism of my prediction in October 2000 that all 13 mitochondrially-encoded proteins would be successfully expressed from nuclear transgenes ("allotopic expression," AE) in cell culture within five years. 6 As I have explained elsewhere, 7 my overoptimism on that score was purely with regard to whether serious efforts to engineer such transgenes would begin soon. I anticipated at that time that a recently-conducted demonstration of successful allotopic expression of one of these genes would imminently be published in Science, where it was in review, but in fact, and for reasons unrelated to the quality of the study, it was only published four years later 8 (in, I am proud to say, this journal 9, 10 ). AE has long been considered realistic by many mitochondriologists but overambitious by funding agencies, a disconnect that a high-profile report of success might have abruptly altered. From a scientific standpoint, however, no new reasons have emerged to suggest that AE is infeasible, so I still claim that it can be achieved within five years of the initiation of adequate funding. I therefore disagree with Warner that my erroneous prediction implies anything about the futility or otherwise of trying to predict the time course of scientific progress.
Safety. SENS does not discuss germ-line gene therapy, so Warner's point that such therapy is ethically problematic at this time is not relevant to SENS. Somatic gene therapy indeed has a long way to go, but, in view of the continued and accelerating effort to advance it, and especially since gene therapy (even with non-randomly-inserting vectors 11 ) already works rather well in mice, its current limitations are hardly reasons not to develop the appropriate cargo in anticipation of such advances. Rather, we should consider how foolish and guilty we will feel if breakthroughs in gene delivery are made and we have not begun to develop the constructs that would be worth delivering.
Warner then discusses WILT, the SENS strand proposed to address cancer. However, in rejecting it he simply lists aspects of it that have been thoroughly addressed in my publications 12, 13 and offers no challenges to my analysis given there. Thus, he gives no specific reasons for doubting my claim that it can be implemented safely and effectively within a few decades. In my view, to call confidence in WILT a "leap of faith" on the basis of such little analysis is itself a leap of faith.
Feasibility. The fact that SENS is a repair and maintenance strategy gives it an advantage for testing in long-lived mammals that Warner apparently overlooks: namely, that effective interventions of that type can yield positive results in a small fraction of the organism's lifespan. SENS, if it works, should greatly reduce the mortality rates of organisms to which it is applied, even when those organisms have had no treatment before that time. It is thus realistic to expect that statistically significant results in primates with a life expectancy of, say, 30 years could be obtained after only a year or two, using animals that were already approaching their life expectancy at birth when treatment began. Biomarkers of remaining life expectancy (whose relevance for assessing the efficacy of treatments is in any case questionable 14 ) are therefore not required.
Warner's remarks concerning human trials are also short-sighted, in my view, since they presume that such trials would be conducted in a regulatory environment resembling today's. I have argued "escape velocity" of subsequent SENS development 16 (the rate at which the SENS components would need to be improved in efficacy in order to deliver the same degree of life extension as if they were perfect) has recently been shown to be quite modest: roughly a doubling of efficacy every 40 years. 17 Warner concludes that, since (in his opinion) SENS is so unlikely to work, we should not allocate resources to it but instead continue to focus our resources on funding additional exploratory research. There is indeed a threshold probability of success below which it would be inappropriate to pursue a venture so ambitious and expensive as the SENS agenda; I have never disputed this. However, one can only assess accurately whether SENS's probability of success exceeds that threshold by examining its details closely. The shortcomings of Warner's analysis reinforce my belief that the overwhelming majority of those who have expressed pessimism concerning SENS's prospects have yet to study my publications (and, most importantly, the relevant experimental work that I cite) thoroughly enough to make such an assessment.
